Aberdeen Group’s Apogee Therapeutics APGE Stock Holding History

Aberdeen Group’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-143,379	Closed	-$12.1M	–	937
2026 Q1	$12.1M	Buy	143,379 +107,276	+297%	+$7.79M	0.02%	558
2025 Q4	$2.73M	Sell	36,103 -18,657	-34%	-$1.18M	﹤0.01%	750
2025 Q3	$2.18M	Buy	+54,760	New	+$2.09M	﹤0.01%	772

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Aberdeen Group's APGE Position: Q2 2026 in Review

Aberdeen Group sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 143,379 shares — an estimated $12.1M sold.

Aberdeen Group first reported a position in APGE in Q3 2025 and held it in 3 quarters. The position peaked at $12.1M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Aberdeen Group reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
Aberdeen Group sold 143,379 Apogee Therapeutics shares in Q2 2026, an estimated $12.1M.
Aberdeen Group first reported a position in Apogee Therapeutics in Q3 2025 and held it in 3 quarters.
Aberdeen Group's Apogee Therapeutics position peaked at $12.1M in Q1 2026.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.